Review of eight pharmacoeconomics studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis - Doan, QV; Chiou, CF; Dubois, RW (J Manag Care Pharm, 2006)